colorectal cancer
Conditions
Interventions
None listed
Sponsors
Japan Clinical Cancer Research Organization (JACCRO)
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: (1) Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0-2 (2) unresectable or metastatic colorectal cancer (3) histopathologically confirmed adenocarcinoma with RAS wild-type (4) 20 years and more at informed consent (5) refractory disease or unable to tolerate after gained the response of fluoropyrimidine containing regimen (6) schedule the testing of OncoBEAMTM RAS CRC kit (7) An estimated life expectancy of at least 90 days after enrollment (8) Ability to understand and the willingness to sign a written informed consent document
Exclusion criteria
Exclusion criteria: (1) Another malignancy with less than 5 disease-free years (2) Patients whose participation in the trial was judged to be inappropriate by the attending doctor
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| the frequency of RAS wild in ctDNA | — |
Secondary
| Measure | Time frame |
|---|---|
| (1) mutation allele frequency of RAS mutation in ctDNA (2) regarding all chemotherapies in enrolled patients overall response rate:ORR disease control rate:DCR overall survival:OS progression-free survival:PFS (3) regarding anti-EGFR antibody containing regimen in enrolled patients treatment cycle safety | — |
Countries
Japan
Contacts
Public ContactNaoki IZAWA
St. Marianna University School of Medicine Department of Clinical Oncology
Outcome results
None listed